natgillin/translations-raw huggingface dataset:
The isolated nucleic acid molecule of claim 8, comprising the nucleotide sequence set forth in SEQ ID NO:17. 
Izolirana molekula nukleinske kiseline iz patentnog zahtjeva 8, koja sadrži nukleotidnu sekvencu danu u SEQ ID BR: 17.
A prokaryotic or eukaryotic host cell comprising the isolated nucleic acid molecule according to claim 8, wherein said host cell optionally is at least one selected from E. coli BL21Star(DE3), other E. coli cell, yeast, COS-1, COS-7, HEK293, BHK21, CHO, BSC-1, Hep G2, 653, SP2/0, 293, HeLa, myeloma, or lymphoma cells, or any derivative, immortalized or transformed cell thereof. 
Prokariotska ili eukariotska domaćinska stanica koja sadrži izoliranu molekulu nukleinske kiseline prema patentnom zahtjevu 8, pri čemu je navedena domaćinska stanica opcionalno barem jedna izabrana od E. koli BL21Star (DE3), druga ćelija E. koli, kvasca, COS-1, COS- 7, HEK293, BHK21, CHO, BSC-1, Hep G2, 653, SP2/0, 293, HeLa, mijeloma ili stanica limfoma, ili bilo koji njihovi derivati, besmrtne ili transformirane stanice.
A composition comprising the protein scaffold of any one of claims 1-3 and at least one pharmaceutically acceptable carrier or diluent, optionally further comprising at least one compound or polypeptide selected from a detectable label or reporter, a TNF antagonist, an anti-infective drug, a cardiovascular (CV) system drug, a central nervous system (CNS) drug, an autonomic nervous system (ANS) drug, a respiratory tract drug, a gastrointestinal (GI) tract drug, a hormonal drug, a drug for fluid or electrolyte balance, a hematologic drug, an antineoplastic, an immunomodulation drug, an opthalmic, otic or nasal drug, a topical drug, a nutritional drug, a cytokine, and a cytokine antagonist. 
Sastav koji sadrži proteinsku platformu prema bilo kojem od patentnih zahtjeva 1-3 i najmanje jedan farmaceutski prihvatljiv nosač ili diluens, opcionalno dalje sadržavajući najmanje jedan spoj ili polipeptid odabran od detektabilnih oznaka ili reportera, TNF antagonista, antiinfektivnog lijeka, lijeka kardiovaskularnog (CV) sustava, lijeka centralnog živčanog sustava (CNS), lijeka autonomnog živčanog sustava (ANS), lijeka respiratornog trakta, lijeka gastrointestinalnog (GI) trakta, hormonskog lijeka, lijeka za ravnotežu tekućina ili elektrolita, hematološkog lijeka, antineoplastičnog, imunomodulacijskog lijeka, oftalmološkog, otičkog ili nazalnog lijeka, topičkog lijeka, nutricionog lijeka, citokina, ili antagonista citokina.
A medical device, comprising the protein scaffold of any one of claims 1-3, wherein said device is suitable for contacting or administering said protein scaffold by at least one mode selected from parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracerebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, intralesional, bolus, vaginal, rectal, buccal, sublingual, intranasal, and transdermal. 
Medicinski uređaj, koji sadrži proteinsku platformu prema bilo kojem od patentnih zahtjeva 1-3, pri čemu je navedeni uređaj pogodan za dovođenje u dodir ili primjenu navedene proteinske platforme najmanje jednim od slijedećih načina, izabrano od, parenteralnog, supkutanog, intramuskularnog, intravenoznog, intraartikularnog, intrabronhojalng, intraabdominalnog, intrakapsularnog, intrakartilaginoznog, intrakavitarnog, intracelularnog, intracerebelarnog, intracerebroventrikularnog, intrakoličnog, intracervikalnog, intragastičnog, intrahepatičnog, intramiokardialnog, intraostealnog, intrapelvičnog, intraperikardijalnog, intraperitonealnog, intrapleuralnog, intraprostatičnog, intrapulmonalnog, intrarektalnog, intrarenalnog, intraretinalnog, intraspinalnog, intrasinovijalnog, intratorakalnog, intrauterinog, intravezikalnog, intralezionalnog, bolusnog, vaginalnog, rektalnog, bukalnog, sublingvalnog, intranazalnog i transdermalnog.
An article of manufacture for human pharmaceutical or diagnostic use, comprising packaging material and a container comprising a solution or a lyophilized form of the protein scaffold of any one of claims 1-3, wherein said container optionally is a component of a parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracerebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, intralesional, bolus, vaginal, rectal, buccal, sublingual, intranasal, or transdermal delivery device or system. 
Predmet proizvodnje za ljudsku, farmaceutsku ili dijagnostičku upotrebu, koji sadrži materijal za pakiranje i posudu koja sadrži otopinu ili liofilizirani oblik proteinske platforme prema bilo kojem od patentnih zahtjeva 1 do 3, pri čemu je opcionalno navedena posuda komponenta parenteralnog, subkutanog, intramuskularnog, intravenoznog, intraartikularnog, intrabronhialnog, intraabdominalnog, intrakapsularnog, intrakartilaginoznog, intrakavitalnog, intracelularnog, intracerebelarnog, intracerebroventrikularnog, intrakoličnog, intracervikalnog, intragastičnog, intrahepatičnog, intramiokardialnog, intraostealnog, intrapelvičnog, intraperikardijalnog, intraperitonealnog, intrapleuralnog, intraprostatičnog, intrapulmonarnog, intrarektalnog, intrarenalnog, intraretinalnog, intraspinalnog, intrasinovijalnog, intratorakalnog, intrauterinog, intravezikalnog, intralezionalnog, bolusnog, vaginalnog, rektalnog, bukalnog, sublingvalnog, intranazalnog, ili transdermalnog uređaja za isporuku ili sustava.
The inhaler device according to claim 1, wherein each of the two capsule seat parts is suitable for blocking the capsule by interference with walls of the operculum. 
Aparat za inhalaciju prema patentnom zahtjevu 1, pri čemu je svaki od dva sjedišna dijela (14’) kapsule pogodan za blokiranje kapsule (2) interferencijom sa zidovima poklopca.
The inhaler device according to claim 2, wherein each of the two capsule seat parts is suitable to interfere with the walls of the operculum of the capsule without causing perforation or punching of said walls. 
Aparat za inhalaciju prema prethodnom patentnom zahtjevu, pri čemu je svaki od dva sjedišna dijela (14’) kapsule pogodan za međusobno miješanje sa zidovima poklopca kapsule (2) a da se ne prouzroči perforacija, probijanje spomenutih zidova.
Use of 2-((1-methylpropyl)amino)ethanol as an additive in an aqueous suspension, containing from 25 to 62 vol. %, based on the total volume of the suspension, of at least one calcium carbonate-comprising material and having a pH of between 8.5 and 11, for increasing the suspension pH by at least 0.3 pH units, wherein the suspension conductivity change is not more than 100 µS/cm per pH unit. 
Postupak povećavanja pH vodene suspenzije koja sadrži 25 do 62 vol.% barem jednog materijala s kalcijevim karbonatom i ima pH između 8,5 i 11, naznačen time da postupak uključuje korak dodavanja 2-((1-metilpropil)amino)etanola u suspenziju u količini za povećanje pH otopine za najmanje 0,3 pH jedinice, pri čemu promjena vodljivosti otopine nije veća od 100 µS/cm po jedinici pH, naznačen time da je navedeni 2-((1-metilpropil)amino)etanol dodan u navedenu otopinu u količini od 500 do 15000 mg, po litri vodene faze navedene otopine.
is an unsubstituted or substituted 5-6 membered heterocyclyl ring containing 1-2 heteroatoms selected from the group consisting of N and O; wherein said unsubstituted or substituted 5-6 membered heterocyclyl ring formed by R20 and R21 and said unsubstituted or substituted 5-6 membered heterocyclyl ring of R23 are each independently unsubstituted or substituted with a C1-2 alkyl, a pharmaceutically acceptable carrier or exipient and at least one additional therapeutic agent. 
i što su navedeni nesupstituirani ili supstituirani heterociklični prsten s 5-6 članova oblikovani od strane R20 i R21 i naveden nesupstituiran ili supstituiran heterociklični prsten s 5-6 članova oblikovan od R23, nezavisno nesupstituirani ili supstituirani s C1-2 alkil radikalom, koja dalje sadrži farmaceutski prihvatljiv nosač ili ekscipijens i najmanje jedan dodatni terapijski agens izabran iz grupe koju čine nukleotidni inhibitori HIV reverzne transkriptaze.
dissolving the erythromycin or an erythromycin salt or a mixture thereof in the acetone or a mixed solvent comprising acetone under alkaline condition to form a solution of the erythromycin or erythromycin salt; 
otapanje eritromicina ili soli eritromicina ili njihove smjese u acetonu ili smjesi otapala koja sadrži aceton pod alkalnim uvjetima da nastane otopina eritromicina ili sol eritromicina;
The method of any one of claims 2-6, wherein the content of the acetone in the mixed solvent is more than 40%, or more than 50%, or more than 60%, or more than 70%, or more than 80%, or more than 90% by volume; wherein other solvent is an alcohol solvent, an ether solvent, a halogenated solvent, an ester solvent, a ketone solvent other than acetone, water or a combination thereof; wherein the alcohol solvent is a C1-C6 alcohol; the ether solvent is tetrahydrofuran, diethyl ether, dioxane, methyl tert -butyl ether, dimethoxyethane, diethylene glycol dimethyl ether, triethylene glycol dimethyl ether or a combination thereof; the halogenated solvent is dichloromethane, 1,2-dichloroethane, chloroform or a combination thereof; the ester solvent is ethyl acetate, isopropyl acetate, butyl acetate or a combination thereof; and the ketone solvent is butanone. 
Postupak prema bilo kojem od zahtjeva 1-5, naznačen time da je udio acetona u smjesi otapala veći od 40%, ili veći od 50%, ili veći od 60%, ili veći od 70%, ili veći od 80%, ili veći od 90% po volumenu; pri čemu drugo otapalo je alkoholno otapalo, etersko otapalo, halogenirano otapalo, estersko otapalo, ketonsko otapalo osim acetona, voda ili njihova kombinacija; pri čemu alkoholno otapalo je C1-C6 alkohol; etersko otapalo je tetrahidrofuran, dietil eter, dioksan, metil tert-butil eter, dimetoksietan, dietilen glikol dimetil eter, trietilen glikol dimetil eter ili njihova kombinacija; halogenirano otapalo je diklormetan, 1,2-dikloretan, kloroform ili njihova kombinacija; estersko otapalo je etil acetat, izopropil acetat, butil acetate ili njihova kombinacija; i ketonsko otapalo je butanon.
The method of any one of claims 2-8, wherein the pH of the solution in step c is from 6.0 to 8.0, or from 6.0 to 7.5, or from 7.0 to 7.5; wherein the pH adjusting agent is a weak acid, and the weak acid is an inorganic acid, an organic acid or a combination thereof, or the weak acid is dilute acetic acid, dilute hydrochloric acid, dilute sulfuric acid, dilute phosphoric acid, dilute nitric acid or a combination thereof. 
Postupak prema bilo kojem od zahtjeva 1-7, naznačen time da se pH otopine u koraku c) podešava na od 6.0 do 7.5, ili od 7.0 do 7.5 sa slabom kiselinom, te pri čemu slaba kiselina je anorganska kiselina, organska kiselina ili njihova kombinacija, ili slaba kiselina je razrijeđena octena kiselina, razrijeđena solna kiselina, razrijeđena sumporna kiselina, razrijeđena fosforna kiselina, razrijeđena dušična kiselina ili njihova kombinacija.
connecting a magnetic filter (28) across two points in the at least one circuit of pipe work, the method is characterized by the steps of: 
spajanje magnetskog filtera (28) preko dvije točke u barem jednom krugu cijevi, postupak je naznačen koracima:
draining or substantially draining the central heating system of system water, 
ispuštanje ili supstancijalno ispuštanje sustava središnjeg grijanja iz sustava vode,
partially filling the central heating system with system water, 
djelomično punjenje sustava centralnog grijanja sistemskom vodom,
operating the pump (16) to cause circulation of system water around the central heating system and through the filter, 
upravljanje crpkom (16) kako bi voda cirkulirala kroz sustav centralnog grijanja i kroz filter,
removing any debris collected at the filter, and 
uklanjanje ostataka nakupljenih na filter, i
re-filling the central heating system with system water to an operational level. 
ponovno punjenje sustava centralnog grijanja sistemskom vodom do operacijske razine.
A method as claimed in claim 1, in which the steps are carried out sequentially in the order b), a), c) to e). 
Postupak sukladno zahtjevu 1, u kojem se koraci izvode supstancijalno redom b), a), c) do e).
A method as claimed in any preceding claim, including the step of isolating system water flow through the central heating system to each radiator in turn, and applying vibration to the radiator, through which system water is arranged to be passing. 
Postupak sukladno bilo kojem od prethodnih zahtjeva, uključuje korak izoliranja sustava protoka vode kroz sustav centralnog grijanja do svakog radijatora, i primjene vibracije na radijator, kroz čiji je sustav organiziran protok vode.
A method as claimed in any preceding claim in which the central heating system is fully drained and refilled for commissioning after step g). 
Postupak sukladno bilo kojem od prethodnih zahtjeva u kojem je sustav centralnog grijanja potpuno ispražnjen i ponovono napunjen nakon koraka g).
A method as claimed in any preceding claim, in which an inhibitor is added to the central heating system water prior to commissioning of the central heating system. 
Postupak sukladno bilo kojem od prethodnih zahtjeva, u kojem se sustavu centralnog grijanja dodaje inhibitor prije puštanja sustava u rad.
where cycloalkyl refers to a mono-or polycyclic hydrocarbon alkyl, alkenyl or alkynyl group which may form a bridged ring or a spiro ring, and which may have one or more double or triple bond(s). 
gdje se cikloalkil odnosi na mono-ili policikličku skupinu ugljikovodika alkil, alkenil ili alkinil koja može tvoriti premošteni prsten ili spiro prsten, i koja može imati jednu ili više dvostrukih ili trostrukih veza.
R4a is selected from the group consisting of H and C1-8alkyl; 
a je odabran iz skupine koju čine H i C1-8alkil;
A compound according to any one of claims 1 to 9 for use in treatment of a disease or condition selected from the group consisting of cardiovascular disease, inflammatory disease, autoimmune disease and cell proliferative disorder. 
Spoj prema bilo kojem od zahtjeva 1 do 9 naznačen time da je za uporabu za liječenje bolesti ili stanja odabranog iz skupine koju čine kardiovaskularna bolest, upalna bolest, autoimuna bolest i poremećaj proliferacije stanica.
A compound according to any one of claims 1 to 9 for use in treating: a cardiovascular disease selected from the group consisting of restenosis, thrombosis, immune thrombocytopenic purpura, heparin induced thrombocytopenia, dilated cardiomyopathy, sickle cell disease, atherosclerosis, myocardial infarction, vascular inflammation, unstable angina and acute coronary syndromes; 
Spoj prema bilo kojem od zahtjeva 1 do 9 naznačen time da je za uporabu za liječenje: kardiovaskularne bolesti koja je odabrana iz skupine koja se sastoji od restenoze, tromboze, imunološki posredovane trombocitopenične purpure, heparinom inducirane trombocitopenije, dilatirajuće kardiomiopatije, bolesti srpastih stanica, ateroskleroze, infarkta miokarda, vaskularne upale, nestabilne angine pektoris i akutnih koronarnih sindroma;
an inflammatory disease is selected from the group consisting of allergy, asthma, rheumatoid arthritis, B Cell mediated diseases such as Non Hodgkin's Lymphoma, anti phospholipid syndrome, lupus, psoriasis, multiple sclerosis, end stage renal disease and Crohn's disease; 
upalne bolesti koja je odabrana iz skupine koju čine alergija, astma, reumatoidni artritis, bolesti koje su posredovane B stanicama, kao što su ne-Hodgkinov limfom, anti fosfolipidni sindrom, lupus, psorijaza, multipla skleroza, krajnji stadij bubrežne bolesti i Crohnova bolest;
an autoimmune disease selected from the group consisting of hemolytic anemia, immune thrombocytopenic purpura, multiple sclerosis, psoriasis and Sjogren's syndrome; or a cell proliferative disorder selected from the group consisting of leukemia, a lymphoma, myeloproliferative disorders, hematological malignancies, and chronic idiopathic myelofibrosis. 
autoimune bolesti koja je odabrana iz skupine koju čine hemolitička anemija, imunološki posredovana trombocitopenična purpura, multipla skleroza, psorijaza i Sjogrenov sindrom; ili poremećaja proliferacije stanica koji je odabran iz skupine koju čine leukemija, limfom, mijeloproliferativni poremećaji, zloćudne bolesti hematološkog sustava, te kronična idiopatska mijelofibroza.
A kit comprising a composition of claim 11, packaging and instructions for use. 
Komplet naznačen time da sadrži pripravak prema zahtjevu 11, pakiranje i instrukcije za upotrebu.
A pallet container according to claim 1 or claim 2 wherein the pallet includes stacking formations (80, 82) enabling like pallets to be stacked one on top of another. 
Paletni spremnik prema zahtjevu 1 ili zahtjevu 2 naznačen time da paleta uključuje slaganje dijelova (80, 82), koji omogućavaju da se slične palete slažu jedna na drugu.
a load-bearing flexible porous support (2) in the form of a sheet, provided with at least two major outer faces substantially parallel and opposite to each other, said flexible porous support being a nonwoven fibrous support 
nosivu fleksibilnu poroznu potporu (2) oblika lista, s barem dva glavna vanjska lica u osnovi paralelna i međusobno suprotna, fleksibilna porozna potpora je netkana vlaknasta potpora
a resin matrix (3, 3A,3B) applied on at least one face of said support (2) 
matričnu smolu (3, 3A,3B) primijenjenu na barem jednu stranu navedene potpore (2)
Multifunctional structure (1, 1A, 1B, 1C) according to the preceding claim, wherein said resin (3,3A,3B) is applied by coating on said fibrous support (2). 
Multifunkcionalna struktura (1, 1A, 1B, 1C) sukladno prethodnom zahtjevu, pri čemu je navedena smola (3,3A,3B) primijenjena u sloju na navedenoj vlaknastoj strukturi (2).
Multifunctional structure (1, 1A, 1B, 1C) according to any of the preceding claims, wherein said resin (3,3A,3B) is selected from the group of acrylic resins, polyurethane resins, polymer resins. 
Multifunkcionalna struktura (1, 1A, 1B, 1C) sukladno bilo kojem od prethodnih zahtjeva, pri čemu je smola (3,3A,3B) odabrana iz skupine akrilnih smola, poliuretanskih smola, polimerskih smola.
Multifunctional structure (1, 1A, 1B, 1C) according to claim 2, wherein said felt comprises as an alternative or in combination at least one among: polypropylene fibers, polyester fibers, a blend of polypropylene fibers and/or polyester fibers with natural and/or synthetic and/or mineral fibers ranging from 35% to 90%. 
Multifunkcionalna struktura (1, 1A, 1B, 1C) sukladno zahtjevu 2, pri čemu filc obuhvaća kao alternativu ili u kombinaciji barem jedno od: polipropilenska vlakna, poliesterska vlakna, mješavinu polipropilenskih vlakana i/ili poliesterska vlakna s prirodnim i/ili sintetskim i/ili mineralnim vlaknima opsega 35% do 90%.
Multifunctional structure (1, 1A, 1B, 1C) according to the preceding claim, wherein said felt is a felt of polypropylene fibers, preferably fire resistant ones, said polypropylene fibers being alternatively: 
Multifunkcionalna struktura (1, 1A, 1B, 1C) sukladno prethodnom zahtjevu, pri čemu je filc od polipropilenskih vlakana, poželjno vatrootpornih, polipropilenska vlakna su alternativno:
not thermal calendered polypropylene fibers, with a basis weight ranging from 100 g/m2 to 1000 g/m2, 
ne toplinski kalandrirana polipropilenska vlakna, s bazom težine od 100 g/m² to 1000 g/m²,
polypropylene fibers thermal calendered on one side. 
polipropilenska vlakna toplinski kalandrirana s jedne strane.
Multifunctional structure (1, 1 A, 1B, 1C) according claim 4, wherein said felt is a felt of polyester fibers, preferably fire resistant ones, said polyester fibers being alternatively: 
Multifunkcionalna struktura (1, 1 A, 1B, 1C) sukladno zahtjevu 4, pri čemu je filc od poliesterskih vlakana, poželjno vatrootpornih, navedena poliesterska vlakna su alternativno:
Multifunctional structure (1, 1A, 1B, 1C) according to one or more of the preceding claim, wherein said functionalizing fillers (4) are spheroidal hollow solids 
Multifunkcionalna struktura (1, 1A, 1B, 1C) sukladno jednom ili više prethodnih patentnih zahtjeva, pri čemu su navedeni fukcionalizirajući fileri (4) sferoidni šuplji čvrsti predmeti.
Multifunctional structure (1, 1 A, 1B, 1 C) according to one or more of the preceding claim, wherein said functionalizing fillers (4) are full of air. 
Multifunkcionalna struktura (1, 1 A, 1B, 1 C) sukladno jednom ili više prethodnih zahtjeva, pri čemu su funkcionalni fileri (4) puni zraka.
Multifunctional structure (1, 1A, 1B, 1C) according to one or more of the claims 7 to 9, wherein said functionalizing fillers (4) in the pre-expanded condition have a diameter from 30 to 50 micron and/or a solid content from 15%±2% by weight and/or a real density of 36±3 kg/m3 and/or a real volume of 4.2±0.45 l/kg or alternatively in the non-expanded condition they have a diameter ranging from 10 to 16 micron and/or a density lower than or equal to 25 kg/m3. 
Multifunkcionalna struktura (1, 1A, 1B, 1C) sukladno jednom ili više zahtjeva 7 do 9, pri čemu funkcionalizirajući fileri (4) u preekspandiranom stanju imaju promjer 30 do 50 mikrona i/ili udio čvrste tvari 15%+2% mase i/ili stvarnu gustoću 36+3 kg/m³ i/ili stvarni volumen od 0,42 + 0.45 l/kg ili altenativno u neekspandiranom stanju imaju promjer opsega 10 do 16 mikrona i/ili gustoću nižu ili jednaku 25 kg/m³.
Multifunctional structure (1, 1A, 1B, 1C) according to one or more of the preceding claims, wherein said functionalizing fillers (4, 4A) are filled in said resin (2) in percentage ranging from 5% to 45% by volume, preferably 15%±5%. 
Multifunkcionalna struktura (1, 1A, 1B, 1C) sukladno jednom ili više prethodnih zahtjeva, pri čemu su funkcionalni fileri (4, 4A) punjeni u navedenoj smoli (2) u postotku od 5% do 45% volumena, poželjno 15%+5%.
Method for manufacturing a multifunctional structure (1, 1A, 1B, 1C) according to one or more of the preceding claims, characterized in that it comprises a preliminary step for applying a resin filled with functionalizing fillers to a porous support and a subsequent step heating and drying the filled resin. 
Postupak proizvodnje multifunkcionalne strukture (1, 1A, 1B, 1C) sukladno jednom ili više prethodnih zahtjeva, naznačen time što obuhvaća preliminarni korak primjene smole ispunjene funkcionalnim filerima na poroznu potporu i sljedeći korak zagrijavanja i sušenja ispunjene smole.
A method of making a tablet for hot extraction of espresso beverages, comprising the steps of: 
Postupak izrade tableta za vruću ekstrakciju espresso napitaka, obuhvaća korake:
homogenizing the moistened dose to a substantially uniform residual moisture; 
homogenizacija vlažne doze do u osnovi jednoličnog ostatka vlage;
forming the moistened powder mixture dose by compression to form a tablet (C) having a desired shape; 
formiranje doze vlažne mješavine praha kompresijom kako bi se formirala tableta (C) željenog oblika;
Method as claimed in claim 1, wherein said electromagnetic wave irradiation step g) is carried out at the end of said forming step e) while continuously compressing the dose throughout the irradiation step. 
Postupak sukladno zahtjevu 1, pri čemu je korak iradijacije elektromagnetskim valovima g) izvršen na kraju koraka formiranja e) pri čemu kontinuirano komprimira dozu kroz korak iradijacije.
Method as claimed in claim 3, wherein the compression step is carried out at a pressure (P) ranging from 1 bar to 5 bar, preferably of about 2.5 bar. 
Postupak sukladno zahtjevu 3, pri čemu se kompresijski korak izvodi pod tlakom (P) opsega 1 bar do 5 bara, poželjno od oko 2.5 bara.